Carisma Therapeutics Announces Changes to its Board of Directors
Carisma Therapeutics (Nasdaq: CARM) has announced changes to its Board of Directors. Sohanya Cheng, MBA will join the board effective October 31, 2024, while Michael Torok will step down on the same date due to other professional commitments. Board Chair Sanford Zweifach highlighted Cheng's experience in oncology, leadership, strategic planning, and commercialization as valuable assets for advancing the company's portfolio. Cheng expressed enthusiasm about supporting Carisma's mission in developing innovative immunotherapies and strengthening its position in engineered macrophages.
Carisma Therapeutics (Nasdaq: CARM) ha annunciato modifiche al suo Consiglio di Amministrazione. Sohanya Cheng, MBA entrerà a far parte del consiglio a partire dal 31 ottobre 2024, mentre Michael Torok si dimetterà nella stessa data a causa di altri impegni professionali. Il presidente del consiglio, Sanford Zweifach, ha messo in evidenza l'esperienza di Cheng nell'oncologia, nella leadership, nella pianificazione strategica e nella commercializzazione come risorse preziose per far progredire il portafoglio dell'azienda. Cheng ha espresso entusiasmo nel supportare la missione di Carisma nel sviluppare immunoterapie innovative e nell'afforzare la sua posizione nei macropagi ingegnerizzati.
Carisma Therapeutics (Nasdaq: CARM) ha anunciado cambios en su Junta Directiva. Sohanya Cheng, MBA se unirá a la junta a partir del 31 de octubre de 2024, mientras que Michael Torok renunciará en la misma fecha debido a otros compromisos profesionales. El presidente de la junta, Sanford Zweifach, destacó la experiencia de Cheng en oncología, liderazgo, planificación estratégica y comercialización como activos valiosos para avanzar en el portafolio de la empresa. Cheng expresó su entusiasmo por apoyar la misión de Carisma en el desarrollo de inmunoterapias innovadoras y en fortalecer su posición en los macrófagos diseñados.
Carisma Therapeutics (Nasdaq: CARM)는 이사회에 대한 변경 사항을 발표했습니다. Sohanya Cheng, MBA가 2024년 10월 31일부터 이사회에 합류하며, Michael Torok는 다른 전문적인 약속으로 인해 같은 날짜에 사임할 예정입니다. 이사회 의장인 Sanford Zweifach는 Cheng의 종양학, 리더십, 전략적 계획 및 상업화에 대한 경험을 회사의 포트폴리오를 발전시키기 위한 귀중한 자산으로 강조했습니다. Cheng는 Carisma의 혁신적인 면역 요법 개발 및 조작된 대식세포에서의 입지를 강화하는 임무를 지원하는 것에 대해 열정을 표명했습니다.
Carisma Therapeutics (Nasdaq: CARM) a annoncé des changements au sein de son Conseil d'Administration. Sohanya Cheng, MBA rejoindra le conseil à partir du 31 octobre 2024, tandis que Michael Torok démissionnera à la même date en raison d'autres engagements professionnels. Le président du conseil, Sanford Zweifach, a souligné l'expérience de Cheng en oncologie, en leadership, en planification stratégique et en commercialisation comme des atouts précieux pour faire avancer le portefeuille de l'entreprise. Cheng a exprimé son enthousiasme à soutenir la mission de Carisma dans le développement d'immunothérapies innovantes et à renforcer sa position dans les macrophages développés.
Carisma Therapeutics (Nasdaq: CARM) hat Änderungen in seinem Vorstand angekündigt. Sohanya Cheng, MBA wird ab dem 31. Oktober 2024 dem Vorstand beitreten, während Michael Torok am selben Datum aufgrund anderer beruflicher Verpflichtungen zurücktritt. Der Vorstandsvorsitzende Sanford Zweifach hob Chengs Erfahrung in der Onkologie, in der Führung, strategischen Planung und Kommerzialisierung als wertvolle Vermögenswerte zur Weiterentwicklung des Unternehmensportfolios hervor. Cheng äußerte ihre Begeisterung, Carismas Mission bei der Entwicklung innovativer Immuntherapien zu unterstützen und die Position des Unternehmens in der Herstellung von ingenieurgestützten Makrophagen zu stärken.
- Addition of board member with expertise in oncology and commercialization
- Strategic strengthening of leadership team with commercial experience
- Loss of board member Michael Torok
Appointment of Sohanya Cheng
Resignation of Michael Torok
"It's a pleasure to welcome Sohanya to our Board," said Sanford Zweifach, Chair of the Carisma Board. "Her broad experience in oncology, alongside her skills in leadership, strategic planning, and commercialization, will be instrumental as we continue to advance our portfolio and strengthen our foundation. We are also thankful to Michael for his valuable service and wish him all the best in his next chapter."
"I am excited to join Carisma's Board and collaborate with the management team as the Company advances its mission to deliver innovative immunotherapies to patients facing serious diseases," said Ms. Cheng. "I look forward to sharing my insights and supporting the Company's strategic goals as it solidifies its position as a leader in engineered macrophages within oncology and beyond."
About Sohanya Cheng, MBA
Ms. Cheng brings over 20 years of experience in biopharmaceutical commercialization and research, with a strong focus on oncology. She currently serves as the EVP, Chief Commercial Officer, and Head of Business Development at Karyopharm Therapeutics. Prior to this, she was Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals. Ms. Cheng also spent over a decade at Amgen in various leadership roles, including Executive Director, Head of Marketing & Sales for multiple myeloma and Head of Oncology National Sales, contributing to the commercialization of key oncology brands. She holds an MBA from the MIT Sloan School of Management and both a BSc and MA from the University of
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-changes-to-its-board-of-directors-302292071.html
SOURCE Carisma Therapeutics Inc.
FAQ
When will Sohanya Cheng join Carisma Therapeutics (CARM) Board of Directors?
Why is Michael Torok leaving Carisma Therapeutics (CARM) Board?
What expertise does Sohanya Cheng bring to Carisma Therapeutics (CARM)?
